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doi:10.1016/j.pedneo.2011.05.006Combined methylmalonic aciduria and homocystinuria, cobalamin (cbl)C type (cblC disease),
the most common inborn error of vitamin B12, is a rare disorder of intracellular cbl metabolism
because of mutations in the MMACHC gene located in chromosome region 1p34.1. It has
become possible to establish phenotypeegenotype correlations and to observe ethnicity-
related trends. This article provides detailed clinical manifestations and outcomes of a Taiwa-
nese infant boy with early-onset cblC disease, heterozygous for c.609G>A and c.567dupT
mutations, although there is limited information about cases with c.609G>A or c.567dupT
mutation in the literature. He had no significant clinical abnormality during his neonatal
period, whereas elevated C3 level was noted at newborn screening. He presented later with
life-threatening manifestations and failure to thrive, which resolved through our treatment,
although delayed development was still noted at 6 months of age. To date, all reported cblC
patients with the c.609G>A mutation have been East Asians. Therefore, we suggest that
c.609G>A should be included in the initial mutation screening tests for a cblC patient in East
Asian populations.
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Defects in vitamin B12 [cobalamin (cbl)] metabolism are
inherited as autosomal recessive disorders and are classi-
fied into the eight genetic complementation groups (cblA-G
and mut). Among them, cblC is the most common.1,2 The
disorder cblC disease (Online Mendelian Inheritance in Man
277400) has combined methylmalonic aciduria (MMA) and
homocystinuria (HCU) because of an early block in the
synthesis of methylcobalamin (MeCbl) and 50-deoxy-
adenosylcobalamin (AdoCbl). These are the cofactors of the
cytoplasmic enzyme methionine synthase and the mito-
chondrial enzyme methylmalonyl-CoA mutase, respec-
tively.1 This rare disorder of intracellular cbl metabolism is
because of mutations in the MMACHC gene located in
chromosome region 1p34.1.2 To date, only 400 known cases
worldwide and more than 50 causal mutations have been
reported.3
Although some patients develop symptoms in childhood,
adolescence, or adulthood, most patients are acutely ill in
their infancy, presenting with failure to thrive, acute
neurologic deterioration, mental retardation, retinopathy,
multiorgan system dysfunction, and hematologic abnor-
malities.4 In general, late-onset patients have better
survival and response to treatment, and fewer neurologic
sequelae compared with early-onset patients.5
The recognition of phenotypeegenotype correlations
and the association of mutations with specific ethnicities
will be useful for the identification of disease-causing
mutations in cblC patients, for carrier detection and
prenatal diagnosis in families where mutations are known,
and in setting up initial screening programs in molecular
diagnostic laboratories.1 This study investigated and
described the clinical manifestations, treatment outcomes,
and developmental evaluations of a Taiwanese male infant
with early-onset cblC disease, heterozygous for c.609G>A
and c.567dupT, who presented at about 1.5 months of age
with life-threatening manifestations and failure to thrive,
whereas no significant clinical abnormality during his
neonatal period except elevated C3 level was noted at
newborn screening.
2. Case Report
A full-term, male neonate was born by normal spontaneous
vaginal delivery to a 21-year-old, G1P1 mother with
uneventful pregnancy. His birth weight was 2650 g, and
Apgar scores were 9 and 10 at 1 minute and 5 minutes,
respectively. Both his parents were Taiwanese, but the
mother was of Chinese ancestry. The parents and siblings
were all alive and well.
However, the patient had elevated C3-acylcarnitine
level of 7.28 mmol/L (upper limit, 4.74) at first newborn
screening. Subsequent data showed the following: C3-
acylcarnitine, 5.7; C3/C2 ratio, 0.63 (upper limit, 0.17);
methionine, 6.13 mmol/L (normal range, 23e59); homo-
cysteine, 219.4 mmol/L (normal range, 5.9-16); and vitamin
B12 level, 1226 pg/mL (normal range, 200e950). Therefore,
presymptomatic combined MMA and HCU was highly
suspected. However, at 1.5 months of age, the patient
presented with feeding difficulty, poor activity, paleappearance, and failure to thrive, such that his weight,
height, and head circumference were all less than the third
percentile. Other laboratory data showed pancytopenia
(leukocyte count, 2.3 109/L; hemoglobin, 4.7 g/dL; and
platelet count, 15 109/L); normal ammonia level of
35 mg/dL (normal range, 20e92); and metabolic acidosis
with bicarbonate level of 17.7 mmol/L, lactate level of
34 mg/dL (normal range, 6.3e18.9), and normal anion gap
of 9.3 mEq/L.
On admission, cyanocobalamin (CNCbl) and carnitine as
well as other supportive treatments were started as soon as
possible. However, there was a sudden onset of seizure,
and respiratory failure occurred 3 days later, requiring
intubation with mechanical ventilator support. Meanwhile,
the patient’s metabolic acidosis worsened, and elevated
ammonia and lactate levels were noted. CNCbl was
replaced with hydroxycobalamin (OHCbl), and betaine was
added to the carnitine treatment a day after intubation.
The metabolic acidosis resolved shortly, and the patient
was extubated 1 day later. The elevated ammonia and
lactate levels, leukopenia, and thrombocytopenia all
resolved gradually within 1 week after the new regimen was
started.
At 2 months of age, the patient’s brain magnetic reso-
nance imaging showed mild to moderate ventriculomegaly
with enlarged cortical sulci, diffuse mild edematous
change over the bilateral central and subcortical white
matter regions, and delayed myelination. Echocardiogram
and ophthalmology consults revealed neither cardiac nor
ophthalmologic abnormalities. Finally, two mutations,
c.609G>A (p.Trp203X) and c.567dupT (p.Ile190TyrfsX13),
were found to be inherited from paternal and maternal
MMACHC alleles, respectively (Figure 1).
At 6 months of age, the patient’s weight was 7500 g
(15the50th percentile), height was 66 cm (15th percentile),
and head circumference was 39 cm (<3rd percentile),
as well as delayed development (Mental Development
IndexZ 74 and Psychomotor Development IndexZ 55)
were noted. Currently, he is managed with OHCbl 1-mg
intramuscular injections biweekly, carnitine 100 mg/kg/d
divided into three doses, betaine 275 mg/kg/d, and folinic
acid 1 mg three times a day, as well as rehabilitation
programs.
3. Discussion
With the identification of the MMACHC gene, it has become
possible to establish phenotypeegenotype correlations and
to observe ethnicity-related trends.1 The c.271dupA,
together with c.394C>T and c.331C>T, is the most common
mutation.1,3,6 Patients homozygous for c.271dupA invari-
ably have early onset, or within 4 years of life,5 with acute
metabolic decompensation. In contrast, individuals homo-
zygous for c.394C>T reportedly have later onset, with
better treatment response and reversal of neurologic
manifestations.1,3,5,6
The c.271dupA mutation is observed primarily in Euro-
peans, whereas most individuals with c.394C>T are of
Middle Eastern origin.3 Interestingly, patients who are
compound heterozygous for the c.271dupA and c.394C>T
can manifest with a disease that is intermediate between
Figure 1 Two MMACHC mutations, c.609G>A (p.Trp203X) and c.567dupT (p.Ile190TyrfsX13), were found in the patient (II-1).
These were inherited from both paternal (I-1) and maternal (I-2) MMACHC alleles.
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for c.271dupA and late-onset phenotype associated with
homozygosity for c.394C>T. Unfortunately, interpretation
of anticipated phenotype based on this genotype may not
be totally reliable.1
The newest progress of newborn screening with tandem
mass spectrometry allows the identification of inborn errors,
including MMA and HCU, which cannot be approached by
traditional methods. Elevated C3 and high methionine levels
are usually detected on screening of MMA and HCU,
respectively.7 However, variable values of methionine levels
can be present in patients with HCU, depending on which
defective part of the metabolic pathway takes place.
Because MeCbl is required for the activity of methionine
synthase, which converts homocysteine to methionine, low
to normal plasma methionine levels will be detected in
patients with cblC disease because of impaired MeCbl
synthesis.8 Moreover, it is thought that the most reliable
screening method for HCU, regardless of severity or cause, is
the measurement of total homocysteine directly.9 There-
fore, it is important to check the homocysteine levels in
blood and urine to rule out combination with HCU in cases
where MMA is highly suspected on the initial newborn
screening.
This patient could be diagnosed with combined MMA and
HCU by means of newborn screening and subsequent
biochemical tests before 1 month of age, who belongs to
the early-onset group of cblC disease. We did not treat the
patient in the beginning until he presented later with life-
threatening clinical manifestations, which fortunately
responded well to our treatment. Some authors suggested
progressive neurologic and visual deterioration in the early-
onset cases still occurred despite early intervention with
OHCbl therapy, even as early as prenatal treatment.10e12
However, in the era of newborn screening, it is widely
accepted that early recognition of those rare disordersallows for early treatment before the onset of irreversible
impairment and, in many cases, prevention of catastrophic
health outcomes, including death.13 Therefore, we would
like to suggest that, after the results of newborn screening,
it is important to inform the possibility of poor activity,
feeding difficulty, or even pale appearance, so that parents
can be aware of this condition and send the patient to the
hospital as early as possible; once diagnosed with cblC
disease, therapeutic and supportive treatments must be
considered and implemented, even in the presymptomatic
stage.
The genotype of this patient is compound heterozygous
for c.609G>A and c.567dupT, a nonsense mutation and
a duplication and frameshift mutation, respectively.3 Most
patients homozygous for c.609G>A reported in the litera-
ture have been diagnosed before 1 year of age, and all were
East Asians.2,3 There has been another male Taiwanese
neonate heterozygous for c.609G>A and c.658_660delAAG
diagnosed with cblC disease by means of newborn
screening.3 The present patient is the first Asian and is
the second case with c.567dupT mutation in literature. The
first one was a female Hispanic individual diagnosed at
1 month of age with three MMACHC mutations: c.567dupT
in cis with one c.328_331delAACC allele.3 This article
provides detailed clinical manifestations and outcomes of
a cblC patient, heterozygous for c.609G>A and c.567dupT
mutations, although there is limited information about the
clinical features except for the early onset in those patients
with c.609G>A or c.567dupT mutation reported in the
literature.
Patients with cblC disease, including this one, are
generally unresponsive to treatment with CNCbl but are
more responsive to OHCbl.5,14,15 This phenomenon remains
a puzzle unsolved since the 1970s, when cultured skin
fibroblasts from patients with mutations in the MMACHC
gene were found unable to use CNCbl for the biosynthesis of
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MMACHC gene product (cblC protein) catalyzes a reductive
decyanation reaction of bound CNCbl to cob(II)alamin,
which is a prerequisite for its conversion to the active
cofactor forms used by mammals wherein the cyano ligand
is replaced by a methyl group (in MeCbl) or a 5’-deoxy-
adenosyl group (in AdoCbl). Froese et al14 reported that the
ability of the mutant MMACHC to respond to vitamin
therapy depends on its ability to bind the vitamin with
significant affinity. Mutant MMACHC has decreased ability
to reductively decyanate the CNCbl to cob(II)alamin. With
OHCbl treatment, binding is normal and OHCbl is easily
reduced to cob(II)alamin and passed on to the rest of the
pathway.14,18 However, even the provision of active
cofactors MeCbl and AdoCbl, the major alkylcobalamin
forms found in mammalian tissues, plasma, and milk,
demands their conversion to give cob(I)alamin, which is
oxidized to cob(II)alamin and is subsequently converted to
MeCbl and AdoCbl19; that is, the removal of the alkyl
group of alkylcobalamins entering from circulation intra-
cellularly is necessary, and patient fibroblasts with mutated
MMACHC (cblC protein) are unable to perform dealkylation
reactions.20
In conclusion, we have described a Taiwanese infant boy
with early-onset cblC disease, heterozygous for c.609G>A
and c.567dupT, who was presymptomatic at newborn
screening but later showed life-threatening manifestations.
He is the first Asian and is the second case with c.567dupT
mutation in the literature. Moreover, all reported cblC
patients with the c.609G>A mutation have been East Asians
so far; thus, we suggest that c.609G>A should be included
in the initial mutation screening tests for a cblC patient in
East Asian populations.
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